Literature DB >> 2553719

Poly(ADP-ribose)-mediated post-translational modification of chromatin-associated human topoisomerase I. Inhibitory effects on catalytic activity.

U N Kasid1, B Halligan, L F Liu, A Dritschilo, M Smulson.   

Abstract

We have investigated the association of human topoisomerase I with poly(ADP-ribosylated) domains of chromatin and the effects of this modification on the enzyme activity. In vitro poly(ADP-ribosylation) assays demonstrated that this enzyme was one of the major acceptors for this chromatin-dependent post-translational modification. Western blotting procedures using antibody to topoisomerase I indicated that under extensive poly(ADP-ribosylation) conditions, where a majority of poly(ADP-ribose) acceptor molecules form aggregates, the major population of the topoisomerase I associated with chromatin was apparently non-aggregated. The catalytic activity of the topoisomerase I associated with the poly(ADP-ribosylated) chromatin was 3-5-fold inhibited. Additionally, antibody to poly(ADP-ribose) was used to immunofractionate selectively the modified domains of chromatin. Our data suggests the presence of topoisomerase I, both adjacent and distal to the poly(ADP-ribosylated) sites of chromatin. Unmodified and a significant portion of the modified species of enzyme migrated as approximately 100-kDa proteins. However, the modified form of topoisomerase was noted to be catalytically less active as compared to the enzyme bound to the non-poly(ADP-ribosylated) nucleosomes. These results provide evidence, at the cellular level, for the poly(ADP-ribosylation)-mediated regulation of human topoisomerase I and suggest a functional significance for poly(ADP-ribosylation) in topoisomerase-related processes (replication, transcription, and recombination) in eukaryotes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553719

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Involvement of PARP and poly(ADP-ribosyl)ation in the early stages of apoptosis and DNA replication.

Authors:  C M Simbulan-Rosenthal; D S Rosenthal; S Iyer; H Boulares; M E Smulson
Journal:  Mol Cell Biochem       Date:  1999-03       Impact factor: 3.396

Review 2.  Molecular and biochemical features of poly (ADP-ribose) metabolism.

Authors:  D Lautier; J Lagueux; J Thibodeau; L Ménard; G G Poirier
Journal:  Mol Cell Biochem       Date:  1993-05-26       Impact factor: 3.396

Review 3.  Interaction of poly(ADP-ribose)polymerase with DNA polymerase alpha.

Authors:  S Yoshida; C M Simbulan
Journal:  Mol Cell Biochem       Date:  1994-09       Impact factor: 3.396

Review 4.  DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?

Authors:  A K Larsen; C Gobert
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

5.  Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.

Authors:  Anand G Patel; Karen S Flatten; Paula A Schneider; Nga T Dai; Jennifer S McDonald; Guy G Poirier; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2011-12-12       Impact factor: 5.157

6.  Poly(ADP-ribosyl)ation of p53 in vitro and in vivo modulates binding to its DNA consensus sequence.

Authors:  C M Simbulan-Rosenthal; D S Rosenthal; R B Luo; R Samara; M Jung; A Dritschilo; A Spoonde; M E Smulson
Journal:  Neoplasia       Date:  2001 May-Jun       Impact factor: 5.715

Review 7.  Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?

Authors:  Paul O Hassa; Sandra S Haenni; Michael Elser; Michael O Hottiger
Journal:  Microbiol Mol Biol Rev       Date:  2006-09       Impact factor: 11.056

8.  PARP1 poly(ADP-ribosyl)ates Sox2 to control Sox2 protein levels and FGF4 expression during embryonic stem cell differentiation.

Authors:  Furong Gao; Sung Won Kwon; Yingming Zhao; Ying Jin
Journal:  J Biol Chem       Date:  2009-06-16       Impact factor: 5.157

9.  Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury.

Authors:  Basilia Zingarelli; Paul W Hake; Michael O'Connor; Alvin Denenberg; Sue Kong; Bruce J Aronow
Journal:  Mol Med       Date:  2003 May-Aug       Impact factor: 6.354

10.  The predominant form of mammalian DNA topoisomerase I in vivo has a molecular mass of 100 kDa.

Authors:  D S Samuels; N Shimizu
Journal:  Mol Biol Rep       Date:  1994-03       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.